The first improvement over Lantus, according to Hobbs, is simply the length of time the insulin lasts. While Lantus last…
Tresiba
FDA Approval for Tresiba and Ryzodeg, Long Lasting Insulin Drugs
More than two years after dealing Novo Nordisk a surprising setback, the U.S. Food and Drug Administration has approved …
The Novo Nordisk Pipeline: An Interview with CMO Todd Hobbs
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; a…
Novo Nordisk’s Type 2 Diabetes Drug Xultophy Approved in the EU
Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the…
Novo Nordisk’s Ryzodeg Does The Job With Fewer Injections
Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that R…
Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes
Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced n…
New Tresiba/Victoza Combination Therapy, IDegLira, Shows Improved Glucose Control and Weight Loss
IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration…
FDA Delays Review of Novo Nordisk’s New Drug Applications for Tresiba and Ryzodeg
The U.S. FDA issued a Complete Response Letter regarding the New Drug Applications for Tresiba (insulin degludec) and Ry…
Novo Nordisk’s New Insulins, Tresiba and Ryzodeg, Approved by EU
The European Commission has granted Novo Nordisk marketing authorizations for Tresiba (insulin degludec) and Ryzodeg (in…
Novo Nordisk’s Combination Insulin Ryzodeg Approved in Japan
The Japanese Ministry of Health, Labor and Welfare has approved Novo Nordisk's new combination insulin, Ryzodeg, for the…
